Organizing Committee Cochairs:
Philip D. Greenberg, Fred Hutchinson Cancer Center, Seattle, WA (AACR)
James H. Doroshow, National Cancer Institute, Bethesda, MD (NCI)
Denis A. Lacombe, European Organisation for Research and Treatment of Cancer, Brussels, Belgium (EORTC)

Scientific Committee Cochairs:
Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, TX (AACR)
Tim F. Greten, National Cancer Institute, Bethesda, MD (NCI)
E.G. Elisabeth de Vries, University Medical Centre Groningen, Groningen, Netherlands (EORTC)

Scientific Committee Members:
Christina M. Annunziata, National Cancer Institute, Bethesda, MD
Rosemarie Aurigemma, National Cancer Institute, Bethesda, MD
Bristi Basu, Cancer Research UK Cambridge Institute, Cambridge, England
Johanna Bendell, Roche, Basel, Switzerland
Alice P. Chen, National Cancer Institute, Bethesda, MD
Deborah E. Citrin, National Cancer Institute, Bethesda, MD
Giuseppe Curigliano, University of Milano, European Institute of Oncology, Milano, Italy
Ibiayi Dagogo-Jack, Massachusetts General Hospital Cancer Center, Boston, MA
E.G. Elisabeth de Vries, University Medical Centre Groningen, Groningen, Netherlands
James H. Doroshow, National Cancer Institute, Bethesda, MD
Elena Garralda, Vall d’Hebron Institute of Oncology, Barcelona, Spain
Ignacio Garrido-Laguna, University of Utah Huntsman Cancer Institute, Salt Lake City, UT
Adrian L. Gill, Revolution Medicines, Redwood City, CA
Lyndsay N. Harris, National Cancer Institute, Bethesda, MD
Timothy Heffernan, The University of Texas MD Anderson Cancer Center, Houston, TX
Thomas Hellday, Karolinska Institutet, Stockholm, Sweden
Matthew D. Hellman, AstraZeneca Oncology, New York, NY
David Hyman, Loxo Oncology at Lilly, Indianapolis, IN
Seock Ah Im, Seoul National University, Seoul, Korea
S. Percy Ivy, National Cancer Institute, Bethesda, MD
Filip Janku, Monte Rosa Therapeutics, Boston, MA
Patricia M. LoRusso, Yale Cancer Center, New Haven, CT
Jason J. Luke, UPMC Hillman Cancer Center, Pittsburgh, PA
Ignacio Melero, Clinica Universidad de Navarra, Pamplona, Spain
Gordon B. Mills, OHSU Knight Cancer Institute, Portland, OR
Victor Moreno, START Madrid, Madrid, Spain
Jeffrey A. Moscow, National Cancer Institute, Bethesda, MD
Natalie Ngoi, National University Cancer Institute Singapore, Singapore
Ralph E. Parchment, NCI Frederick, Frederick, MD

* - oral presentation from proffered paper
Sophie C. Postel-Vinay, Institut Gustave Roussy, Paris, France
Jordi Rodón, The University of Texas MD Anderson Cancer Center, Houston, TX
Mark Roschewski, National Cancer Institute, Bethesda, MD
Eytan Ruppin, National Cancer Institute, Bethesda, MD
Kurt A. Schalper, Yale Cancer Center, New Haven, CT
Patrick Schoffski, Catholic University of Leuven, Leuven Cancer Institute, Leuven, Belgium
Alison Schram, Memorial Sloan Kettering Cancer Center, New York, NY
Lesley Seymour, Queen's University, Kingston, ON, Canada
Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA
Fiona Simpkins, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA
Jean-Charles Soria, Amgen Oncology, Thousand Oaks, CA
Ramaprasad Srinivasan, National Cancer Institute, Bethesda, MD
Stefan N. Symeonides, University of Edinburgh, Edinburgh, Scotland
Beverly A. Teicher, National Cancer Institute, Bethesda, MD
Anish Thomas, National Cancer Institute, Bethesda, MD
Samra Turajlic, The Francis Crick Institute, London, England
Eric Van Cutsem, University Hospitals Gasthuisberg / Leuven & KULeuven, Leuven, Belgium
Mike Waring, Northern Institute for Cancer Research, Newcastle upon Tyne, England
Brigitte C. Widemann, National Cancer Institute, Bethesda, MD
Noboru Yamamoto, National Cancer Center Hospital, Tokyo, Japan

1 denotes Executive Committee Member

* - oral presentation from proffered paper
WEDNESDAY, OCTOBER 11

Registration
12:00 pm-7:00 pm | Level 2, Exhibit Hall D Lobby

Educational Session 1: Patient-derived Models to Accelerate Drug Discovery     CME
Session Cochairs: Nathan P. Coussens, Frederick National Laboratory for Cancer Research, Frederick, MD, and Annamaria Rapisarda, Leidos Biomedical Research, Frederick, MD
2:00 pm-3:30 pm | Level 3, Ballroom AB

2:00-2:05  Introduction
  Nathan P. Coussens, Frederick National Laboratory for Cancer Research, Frederick, MD

2:05-2:25  Patient-derived tumor organoids to probe the cancer-immune interface
  Krijn Dijkstra, Netherlands Cancer Institute, Amsterdam, Netherlands

2:25-2:45  High-throughput screening of approved and investigational anticancer agents with patient-derived organoids representing a wide range of histologies
  Annamaria Rapisarda, Leidos Biomedical Research, Frederick, MD

2:45-3:05  Surgical applications of organoid technology: Bench to bedside in therapeutic oncology
  Konstantinos Votanopoulos, Wake Forest University, Winston-Salem, NC

3:05-3:15  Interpretation of patient-specific ex vivo immunotherapy response for ovarian cancer*
  Willemijn Vader, VitroScan, Leiden, Netherlands

3:15-3:30  Panel Discussion / Q&A

Break
3:30 pm-3:45 pm | Level 3, Ballroom Foyer

Educational Session 2: Challenges and Prospects in the Analysis of Spatial and Single Cell Biology     CME
Session Cochairs: Manfred Claassen, University of Tübingen, Tübingen, Germany, and Eytan Ruppin, National Cancer Institute, Bethesda, MD
3:45 pm-5:15 pm | Level 3, Ballroom AB

3:45-3:50  Introduction
  Manfred Claassen, University of Tübingen, Tübingen, Germany

* - oral presentation from proffered paper
3:50-4:10 Inference of intercellular signaling activities in tumor spatial and single-cell transcriptomics, with applications in identifying cancer immunotherapy targets
Peng Jiang, National Cancer Institute, Bethesda, MD

4:10-4:30 Lung cancer evolution in space and time
Nicholas McGranahan, UCL London Cancer Institute, London, England

4:30-4:50 Decoding spatially defined ecosystems in cancer with digital cytometry
Aaron M. Newman, Stanford University, Stanford, CA

4:50-5:00 Single-cell spatial analysis reveals microenvironmental features that contribute to immune discrepancies between adult and pediatric nasopharyngeal carcinomas*
Lanqi Gong, National Cancer Institute, Bethesda, MD

5:00-5:15 Panel Discussion / Q&A

Break
5:15 pm-5:30 pm | Level 3, Ballroom Foyer

Welcome and Keynote Lectures
5:30 pm-7:20 pm | Level 3, Ballroom AB

5:30-5:40 Welcome and Opening Remarks
Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, TX
Tim F. Greten, National Cancer Institute, Bethesda, MD
E.G. Elisabeth de Vries, University Medical Centre Groningen, Groningen, Netherlands

5:40-5:45 Introduction of Keynote Lecturer
Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, TX

5:45-6:30 (Re)emerging principles for drug treatment of cancer
William G. Kaelin, Jr., Dana-Farber Cancer Institute, Boston, MA

6:30-6:35 Introduction of Keynote Lecturer
E.G. Elisabeth de Vries, University Medical Centre Groningen, Groningen, Netherlands

6:35-7:20 Understanding mechanisms of action of modern anticancer drugs
Fabrice André, Institut Gustave Roussy, Villejuif, France

* - oral presentation from proffered paper
Opening Reception
7:30 pm-9:30 pm | Level 3, Boylston Street Hallway

THURSDAY, OCTOBER 12

Registration
7:00 am-5:00 pm | Level 2, Exhibit Hall D Lobby

Continental Breakfast
7:00 am-8:00 am | Level 3, Boylston Street Hallway

Plenary Session 1: Liquid Biopsies in the Clinic: Is It Ready for Prime Time?  
Session Cochairs: Catherine Alix-Panabières, University of Montpellier, Montpellier, France, and Klaus Pantel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
8:00 am-9:40 am | Level 3, Ballroom AB

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 8:00-8:05 | Introduction  
Catherine Alix-Panabières, University of Montpellier, Montpellier, France |
| 8:05-8:25 | European Liquid Biopsy Consortia: From discovery to clinical implementation  
Klaus Pantel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany |
| 8:25-8:30 | Q&A |
| 8:30-8:50 | The power of circulating tumor cells in immuno-oncology  
Catherine Alix-Panabières, University of Montpellier, Montpellier, France |
| 8:50-8:55 | Q&A |
| 8:55-9:15 | Engineering technologies for complex clinical laboratories: Lessons learned with extracellular vesicles  
Shannon L. Stott, Harvard Medical School, Boston, MA |
| 9:15-9:20 | Q&A |
| 9:20-9:40 | Panel Discussion / Q&A |

Break
9:40 am-10:00 am | Level 3, Ballroom Foyer

Plenary Session 2: The Journey of Antibody Drug Conjugate Development  
Session Cochairs: E.G. Elisabeth de Vries, University Medical Centre Groningen, Groningen, Netherlands, and Patricia M. LoRusso, Yale Cancer Center, New Haven, CT
10:00 am-11:40 am | Level 3, Ballroom AB

* - oral presentation from proffered paper
10:00-10:05  Introduction  
E.G. Elisabeth de Vries, University Medical Centre Groningen, Groningen, Netherlands

10:05-10:25  Refining our understanding of ADCs: Drug development insights from 40 years of data  
Raffaele Colombo, Zymeworks, Inc., Vancouver, BC, Canada

10:25-10:30  Q&A

10:30-10:50  Antibody drug conjugates: History does not repeat itself, but it does sometimes rhyme  
Anthony W. Tolcher, NEXT Oncology, San Antonio, TX

10:50-10:55  Q&A

10:55-11:15  Optimizing the safety of antibody-drug conjugates for the treatment of cancer  
Paolo Tarantino, Dana-Farber Cancer Institute, Boston, MA

11:15-11:20  Q&A

11:20-11:40  Panel Discussion

---

**Spotlight on Proffered Papers 1**

Session Chair: Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, TX

11:45 am-12:15 pm | Level 3, Ballroom AB

11:45-11:55  Repotrectinib in patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Update from the pivotal phase 1/2 TRIDENT-1 trial*  
Jessica J. Lin, Massachusetts General Hospital, Boston, MA

11:55-12:05  PRISM high-throughput screening of antibody-drug conjugates uncovers clinically relevant targets*  
Jillian N. Eskra, Broad Institute of MIT and Harvard, Cambridge, MA

12:05-12:15  Tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification following first-line osimertinib: INSIGHT 2 primary analysis*  
Xiuning Le, The University of Texas MD Anderson Cancer Center, Houston, TX

---

**Exhibit Show**

12:00 pm-4:00 pm | Level 2, Exhibit Hall D

**Poster Session A**

12:30 pm-4:00 pm | Level 2, Exhibit Hall D

---

* - oral presentation from proffered paper
Concurrent Sessions 1-3
4:00 pm-5:40 pm

CC1: T-cell Engaging Bispecific Antibodies in Solid Tumors   CME
Session Cochairs: Stéphane Champiat, Institut Gustave Roussy, Villejuif, France, and James H. Doroshow, National Cancer Institute, Bethesda, MD
Level 3, Rooms 302-304

4:00-4:05  Introduction
James H. Doroshow, National Cancer Institute, Bethesda, MD

4:05-4:25  Preclinical development of DuoBody®-CD3xB7H4, a novel CD3 bispecific antibody for the treatment of solid cancers
Farshid Alemdehy, Genmab, Utrecht, Netherlands

4:25-4:30  Q&A

4:30-4:50  Emerging insights from the tebentafusp clinical program
David Berman, Immunocore, Rockville, MD

4:50-4:55  Q&A

4:55-5:15  Next-generation, half-life extended TCR bispecifics for targeting PRAME and beyond
Cedrik M. Britten, Immatics Biotechnologies, Munich, Germany

5:15-5:20  Q&A

5:20-5:40  Panel Discussion / Q&A

CC2: Killing Shapeshifting Tumors: Leveraging Plasticity to Target Tumor Heterogeneity   CME
Session Cochairs: Daniel S. Tan, National Cancer Centre Singapore, Singapore, and Anish Thomas, National Cancer Institute, Bethesda, MD
Level 3, Ballroom C

4:00-4:05  Introduction
Daniel S. Tan, National Cancer Centre Singapore, Singapore

4:05-4:25  The role of extrachromosomal DNA amplifications during cancer progression
Roel Verhaak, Amsterdam University Medical Center, Amsterdam, Netherlands

4:25-4:30  Q&A

4:30-4:50  Small cell lung cancer plasticity shaped by extrachromosomal DNA
Anish Thomas, National Cancer Institute, Bethesda, MD

4:50-4:55  Q&A

4:55-5:15  Targeting the evolutionary drivers of EGFR mutated non-small cell lung cancer

* - oral presentation from proffered paper
Daniel S. Tan, National Cancer Centre Singapore, Singapore

5:15-5:20  Q&A

5:20-5:40  Panel Discussion / Q&A

CC3: The Future of Tumor Agnostic Drug Development  CME
Session Cochairs: Jordi Rodón, The University of Texas MD Anderson Cancer Center, Houston, TX, and Alison Schram, Memorial Sloan Kettering Cancer Center, New York, NY
Level 3, Ballroom AB

4:00-4:05  Introduction
Jordi Rodón, The University of Texas MD Anderson Cancer Center, Houston, TX

4:05-4:25  Clinical activity of lirafugatinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: The ReFocus study
Alison Schram, Memorial Sloan-Kettering Cancer Center, New York, NY

4:25-4:30  Q&A

4:30-4:50  Unleashing the power of precision: Exploring ADCs and beyond in novel tumor-agnostic drug development
Vivek Subbiah, Sarah Cannon Research Institute, Nashville, TN

4:50-4:55  Q&A

4:55-5:15  Design of next-generation precision medicine trials using artificial intelligence
Christophe Le Tourneau, Institute Curie, Paris, France

5:15-5:20  Q&A

5:20-5:40  Panel Discussion / Q&A

DO NOT POST: Speaker Reception and Dinner
7:00 pm-10:00 pm | Harvard Club

FRIDAY, OCTOBER 13

Registration
7:00 am-5:00 pm | Level 2, Exhibit Hall D Lobby

Continental Breakfast
7:00 am-8:00 am | Level 3, Boylston Street Hallway
Plenary Session 3: KRAS CME  
Session Cochairs: Karen M. Cichowski, Brigham and Women’s Hospital, Boston, MA and David S. Hong, The University of Texas MD Anderson Cancer Center, Houston, TX  
8:00 am-9:25 am | Level 3, Ballroom AB

8:00-8:05  Introduction  
David S. Hong, The University of Texas MD Anderson Cancer Center, Houston, TX

8:05-8:12  KRAcking RAS: The current state  
David S. Hong, The University of Texas MD Anderson Cancer Center, Houston, TX

8:13-8:20  Promising combinatorial strategies for KRAS mutant cancers  
Karen M. Cichowski, Brigham and Women’s Hospital, Boston, MA

8:20-8:40  Targeting RAS-addicted cancers with investigational RAS(ON) inhibitors  
W. Clay Gustafson, Revolution Medicines, Redwood City, CA
8:40-8:45  Q&A

8:45-9:05  Clinical translational considerations for co-targeting KRAS and immune checkpoints  
James G. Christensen, Mirati Therapeutics, San Diego, CA
9:05-9:10  Q&A

9:10-9:25  Panel Discussion / Q&A

Break  
9:25 am-9:40 am | Level 3, Ballroom Foyer

Plenary Session 4: New Drugs on the Horizon CME  
Session Cochairs: Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, TX, Tim F. Greten, National Cancer Institute, Bethesda, MD, and E.G. Elisabeth de Vries, University Medical Centre Groningen, Groningen, Netherlands  
9:40 am-11:45 am | Level 3, Ballroom AB

9:40-9:45  Introduction  
E.G. Elisabeth de Vries, University Medical Centre Groningen, Groningen, Netherlands

9:45-10:00  Initial results from first-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in biomarker-selected solid tumors*  
Jordi Rodón, The University of Texas MD Anderson Cancer Center, Houston, TX
10:00-10:05  Q&A

* - oral presentation from proffered paper
10:05-10:20  Discovery of HRO761, a novel, first-in-class clinical stage WRN inhibitor with potent and selective anti-tumor activity in cancers with microsatellite instability*
Marta Cortes-Cros, Novartis Institutes for BioMedical Research, Basel, Switzerland  
10:20-10:25  Q&A
10:25-10:40  MYTHIC: First-in-human (FIH) biomarker-driven phase I trial of PKMYT1 inhibitor lunresertib (lunre) alone and with ATR inhibitor camonsertib (cam) in solid tumors with CCNE1 amplification or deleterious alterations in FBXW7 or PPP2R1A*
Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, TX  
10:40-10:45  Q&A
10:45-11:00  Discovery of covalent NRAS inhibitors targeting the palmitoylation site through imaging-based high-throughput screening*
Zhao Wang, Covant Therapeutics, Boston, MA  
11:00-11:05  Q&A
11:05-11:20  Preliminary safety and pharmacokinetic profiles of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS^{MULTI}(ON) inhibitor in patients with KRAS mutant solid tumors on the Phase 1 trial RMC-6236-001*
Alex I. Spira, NEXT Oncology, Fairfax, VA  
11:20-11:25  Q&A
11:25-11:40  Discovery of VVD-065, a first-in-class allosteric molecular glue of the Keap1-Cul3 E3-ligase complex for the treatment of NRF2-activated cancers*
Matt Patricelli, Vividion Therapeutics, San Diego, CA  
11:40-11:45  Q&A

Spotlight on Proffered Papers 2
Session Chair: Tim F. Greten, National Cancer Institute, Bethesda, MD  
11:50 am-12:20 pm | Level 3, Ballroom AB

11:50-12:00  Novel strategy for RAS-pathway targeting: Initial results from a phase 1b/2 clinical trial of the oral HDAC inhibitor bocodepsin (OKI-179) combined with binimetinib in patients with RAS-pathway mutated solid tumors and NRAS-mutated melanoma*
Rodabe N. Amaria, The University of Texas MD Anderson Cancer Center, Houston, TX  
12:00-12:10  First-in-human dose-expansion study of NBF-006, a novel investigational siRNA targeting GSTP, in patients with KRAS-mutated non-small cell lung cancer*
Alexander I. Spira, NEXT Oncology, Fairfax, VA

* - oral presentation from proffered paper
12:10-12:20 Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRAS\textsuperscript{G12C} (ON) inhibitor, in patients with or without prior KRAS\textsuperscript{G12C} (OFF) inhibitor treatment*  
Pasi A. Jänne, Dana Farber Cancer Institute, Boston, MA

Exhibit Show
12:00 pm-4:00 pm | Level 2, Exhibit Hall D

Poster Session B
12:30 pm-4:00 pm | Level 2, Exhibit Hall D

Concurrent Sessions 4-6
4:00 pm-5:40 pm

CC4: Targeting Stromal Cells in Cancer Immunotherapy
Session Cochairs: Ellen Puré, University of Pennsylvania, Philadelphia, PA, and David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
Level 3, Ballroom C

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00-4:05</td>
<td>Introduction</td>
<td>David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY</td>
</tr>
<tr>
<td>4:05-4:25</td>
<td>CAF-immune interactions in the tumor microenvironment</td>
<td>Ruth Scherz-Shouval, Weizmann Institute of Science, Rehovot, Israel</td>
</tr>
<tr>
<td>4:25-4:30</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>4:30-4:50</td>
<td>Dichotomous roles of the pancreatic tumour microenvironment</td>
<td>Claus Jorgensen, CRUK Manchester Institute, University of Manchester, Manchester, England</td>
</tr>
<tr>
<td>4:50-4:55</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>4:55-5:15</td>
<td>Mechanisms and consequences of pancreatic cancer stromal evolution</td>
<td>Mara H. Sherman, Memorial Sloan Kettering Cancer Center, New York, NY</td>
</tr>
<tr>
<td>5:15-5:20</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>5:20-5:40</td>
<td>Panel Discussion / Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

CC5: Large-Scale Multicenter Platform Trials: Combine and Conquer
Session Cochairs: Funda Meric-Bernstam, The University of Texas MD Anderson Cancer Center, Houston, TX, and Beverly A. Teicher, National Cancer Institute, Bethesda, MD
Level 3, Ballroom AB

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00-4:05</td>
<td>Introduction</td>
<td></td>
</tr>
</tbody>
</table>
Beverly A. Teicher, National Cancer Institute, Bethesda, MD

4:05-4:25  NCI ComboMATCH  
Funda Meric-Bernstam, The University of Texas MD Anderson Cancer Center, Houston, TX

4:25-4:30  Q&A

4:30-4:50  Platform neoadjuvant biomarker-driven trial in patients with gastroesophageal adenocarcinoma  
Elena R. Elimova, Princess Margaret Cancer Centre, Toronto, ON, Canada

4:50-4:55  Q&A

4:55-5:15  DRUP (Drug Rediscovery Protocol): Facilitating personalized access to existing anticanic drugs  
Henk M.W. Verheul, Erasmus MC Rotterdam, Rotterdam, Netherlands

5:15-5:20  Q&A

5:20-5:40  Panel Discussion / Q&A

CC6: Unmet Needs and Opportunities to Advance Therapies for Rare Cancers  
CME  
Session Co-chairs: Timothy Heffernan, The University of Texas MD Anderson Cancer Center, Houston, TX, and Brigitte C. Widemann, National Cancer Institute, Bethesda, MD

Level 3, Rooms 302-304

4:00-4:05  Introduction  
Timothy Heffernan, The University of Texas MD Anderson Cancer Center, Houston, TX

4:05-4:25  Realizing clinical trials for rare pediatric cancers  
Brigitte C. Widemann, National Cancer Institute, Bethesda, MD

4:25-4:30  Q&A

4:30-4:50  New approaches to targeting rare fusion driven pediatric cancers  
Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, MA

4:50-4:55  Q&A

4:55-5:15  Power of data and AI in drug development for rare cancers  
Bissan Al-Lazikani, The University of Texas MD Anderson Cancer Center, Houston, TX

5:15-5:20  Q&A

5:20-5:40  Panel Discussion / Q&A
Chemistry in Cancer Research (CICR) Town Hall:
Approaches to Targeting the Guardian of the Genome, p53

Not CME

6:00 pm-7:30 pm | Level 3, Room 312

6:00-6:20 Networking

6:20-6:30 Welcoming Remarks, Overview of 2023-2024 CICR Working Group
Lori Friedman, ORIC Pharmaceuticals, San Francisco, CA
Chemistry in Cancer Research Working Group Steering Committee Member

6:30-6:45 Discovery and development of PC14586, a first-in-class small molecule reactivator of p53 Y220C
Leila Alland, PMV Pharmaceuticals, Cranbury, NJ

6:45-7:00 Design-rules for stapled peptides with in vivo activity and their application to Mdm2/X antagonists
Charles Johannes, Consultant, EPOC Scientific, Boston, MA

7:00-7:15 AceTAC, a novel, innovative, and targeted protein acetylation modality
Md Kabir, Icahn School of Medicine at Mount Sinai, New York, NY

7:15-7:30 Panel Discussion

SATURDAY, OCTOBER 14

Registration
7:00 am-5:00 pm | Level 2, Exhibit Hall D Lobby

Continental Breakfast
7:00 am-8:00 am | Level 3, Boylston Street Hallway

Plenary Session 5: Targeting the DNA Damage Response:
Lessons from the Past, Looking into the Future CME
Session Cochairs: S. Percy Ivy, National Cancer Institute, Bethesda, MD, and Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, TX
8:00 am-9:40 am | Level 3, Ballroom AB

8:00-8:05 Introduction
S. Percy Ivy, National Cancer Institute, Bethesda, MD

8:05-8:25 Learning from the past, looking to the future in targeting the DNA damage
response
Thomas Helleday, Karolinska Institutet, Stockholm, Sweden
8:25-8:30 Q&A

8:30-8:50 New opportunities to target the ATR dependency of cancer cells
Lee Zou, Duke University School of Medicine, Durham, NC
8:50-8:55 Q&A

8:55-9:15 Targeting adaptive responses in cancer through SMMART clinical trials
Gordon B. Mills, OHSU Knight Cancer Institute, Portland, OR
9:15-9:20 Q&A

9:20-9:40 Panel Discussion

Break
9:40 am-10:00 am | Level 3, Ballroom Foyer

Concurrent Sessions 7-9
10:00 am-11:40 am

CC7: Glyco-immunology in Cancer Drug Development CME
Session Cochairs: Li Peng, Palleon Pharmaceuticals, Waltham, MA, and Matthew G. Vander Heiden, Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA
Level 3, Rooms 302-304

10:00-10:05 Introduction
Matthew G. Vander Heiden, Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA

10:05-10:25 Stromal cell sialylation as an immunosuppressive target in the CRC tumor microenvironment
Aideen E. Ryan, University of Galway, Galway, Ireland
10:25-10:30 Q&A

10:30-10:50 Antibody-lectin chimeras for glyco-immune checkpoint blockade
Jessica C. Stark, Stanford University, Stanford, CA
10:50-10:55 Q&A

10:55-11:15 Engineering human sialidase as novel cancer therapeutics by targeting sialoglycans
Li Peng, Palleon Pharmaceuticals, Waltham, MA
11:15-11:20 Q&A

11:20-11:40 Panel Discussion / Q&A

* - oral presentation from proffered paper
CC8: Targeted and Immunotherapy Approaches Against p53  
Session Cochairs: Ecaterina E. Dumbrava, The University of Texas MD Anderson Cancer Center, Houston, TX, and James C. Yang, National Cancer Institute, Bethesda, MD  
Level 3, Ballroom C

10:00-10:05  Introduction  
Ecaterina E. Dumbrava, The University of Texas MD Anderson Cancer Center, Houston, TX

10:05-10:25  Small molecular approaches to tackling p53  
Aparna Parikh, Massachusetts General Hospital, Boston, MA

10:25-10:30  Q&A

10:30-10:50  Targeting MDM2 in solid tumors  
Ecaterina E. Dumbrava, The University of Texas MD Anderson Cancer Center, Houston, TX

10:50-10:55  Q&A

10:55-11:15  T-cells targeting common p53 neoantigens in epithelial cancers  
James C. Yang, National Cancer Institute, Bethesda, MD

11:15-11:20  Q&A

11:20-11:40  Panel Discussion / Q&A

CC9: Advances in Targeted Protein Degradation and Induced Proximity  
Session Cochairs: Danette L. Daniels, Foghorn Therapeutics, Cambridge, MA, and Benjamin L. Ebert, Dana-Farber Cancer Institute, Boston, MA  
Level 3, Ballroom AB

10:00-10:05  Introduction  
Danette L. Daniels, Foghorn Therapeutics, Cambridge, MA

10:05-10:25  Molecular glue degraders  
Benjamin L. Ebert, Dana-Farber Cancer Institute, Boston, MA

10:25-10:30  Q&A

10:30-10:50  Reimagining druggability using chemoproteomic platforms  
Daniel K. Nomura, University of California, Berkeley, CA

10:50-10:55  Q&A

10:55-11:15  Expanding the druggable genome with molecular glues  
Mary Matyskiela, Neomorph, Inc., San Diego, CA

* - oral presentation from proffered paper
Spotlight on Proffered Papers 3  
Session Chair: E.G. Elisabeth de Vries, University Medical Centre Groningen, Groningen, Netherlands
11:45 am-12:15 pm | Level 3, Ballroom AB

11:45-11:55  Determining the mechanism of action of the anti-ENTPD2 antibody, KAZ954*
Deborah Knee, Novartis Institutes for BioMedical Research, San Diego, CA

11:55-12:05  Large-scale organoid panel drug screening to short-track clinically-relevant output*
Mariusz Madej, Crown Bioscience, Leiden, Netherlands

12:05-12:15  Discovery and clinical evaluation of a potent and selective A2A/2B dual receptor antagonist*
Duane DeMong, Merck & Company, Boston, MA

Exhibit Show
12:00 pm-4:00 pm | Level 2, Exhibit Hall D

Poster Session C
12:30 pm-4:00 pm | Level 2, Exhibit Hall D

Concurrent Sessions 10-12
4:00 pm-5:40 pm

CC10: Next-generation Cytokine Engineering for Cancer  
Session Cochairs: Naiyer A. Rizvi, Synthekine, Menlo Park, CA, and Jamie B. Spangler, Johns Hopkins Medicine, Baltimore, MD
Level 3, Rooms 302-304

4:00-4:05  Introduction
Naiyer A. Rizvi, Synthekine, Menlo Park, CA

4:05-4:25  Tumor-specific delivery of immune-activating cytokine/antibody fusion proteins
Jamie B. Spangler, Johns Hopkins Medicine, Baltimore, MD

4:25-4:30  Q&A

4:30-4:50  Engineered IL-12 delivery to the tumor matrix to achieve enhanced efficacy and safety
Jun Ishihara, Imperial College London, London, England

4:50-4:55  Q&A

* - oral presentation from proffered paper
4:55-5:15 REGN10597: A PD-1-targeted, receptor-masked wild type IL-2 with improved therapeutic window for cancer immunotherapy
Tong Zhang, Regeneron Pharmaceuticals, Inc., Tarrytown, NY

5:15-5:20 Q&A

5:20-5:40 Panel Discussion / Q&A

CC11: Emerging T Cell Checkpoints Beyond PD1, CTLA4, and LAG3
Session Cochairs: Ana C. Anderson, Brigham and Women’s Hospital, Boston, MA, and Maria Jose de Miguel, START Madrid, Madrid, Spain
Level 3, Ballroom C

4:00-4:05 Introduction
Maria Jose de Miguel, START Madrid, Madrid, Spain

4:05-4:25 Targeting adenosine receptor and transport for cancer immunotherapy
John Stagg, University of Montreal, Montreal, QC, Canada

4:25-4:30 Q&A

4:30-4:50 PVRIG: An emerging target in the IO landscape
Drew W. Rasco, South Texas Accelerated Research Therapeutics, San Antonio, TX

4:50-4:55 Q&A

4:55-5:15 Role of Tigit in regulating tumor immune infusions
Lloyd Bod, Massachusetts General Cancer Center, Boston, MA

5:15-5:20 Q&A

5:20-5:40 Panel Discussion / Q&A

CC12: Expanding Horizons for Drug Screening: From Preclinical Discovery to Clinical Development
Session Cochairs: Matthew Garnet, Wellcome Sanger Institute, Cambridge, England, and Barry R. O’Keefe, National Cancer Institute, Bethesda, MD
Level 3, Ballroom AB

4:00-4:05 Introduction
Matthew Garnet, Wellcome Sanger Institute, Cambridge, England

4:05-4:25 Integrating natural product samples back into drug screening programs
Barry R. O’Keefe, National Cancer Institute, Bethesda, MD

4:25-4:30 Q&A
4:30-4:50 Investigating adaptive phenotypic plasticity as an early cancer driver in response to anti-cancer treatment for improved treatment strategies

4:50-4:55 Q&A

4:55-5:15 Large-scale pan-cancer screen to identify actionable combinations
Claire Crafter, AstraZeneca, Cambridge, England

5:15-5:20 Q&A

5:20-5:40 From targeted phenotypic screen to NXP800: A clinical stage activator of the integrated stress response for the treatment of ARID1A-mutated ovarian carcinoma

5:40-5:45 Q&A

5:45-6:00 Panel Discussion / Q&A

SUNDAY, OCTOBER 15

Registration
7:00 am-1:00 pm | Level 2, Exhibit Hall D Lobby

Continental Breakfast
7:00 am-8:00 am | Level 3, Boylston Street Hallway

Plenary Session 6: Expanding the Frontiers of T Cell Therapy
Session Cochairs: Benjamin C. Creelan, Moffitt Cancer Center, Tampa, FL, and Elena Garralda, Vall d’Hebron Institute of Oncology, Barcelona, Spain
8:00 am-9:40 am | Level 3, Ballroom AB

8:00-8:05 Introduction
Elena Garralda, Vall d’Hebron Institute of Oncology, Barcelona, Spain

8:05-8:25 TIL therapy for solid tumors: Next steps
Elena Garralda, Vall d’Hebron Institute of Oncology, Barcelona, Spain

8:25-8:30 Q&A

8:30-8:50 Next generation CAR-Ts for solid tumors: A focus into the progress expected for CARs in solid tumors
Salman R. Punekar, NYU Langone Health Perlmutter Cancer Center, New York, NY

8:50-8:55 Q&A

* - oral presentation from proffered paper
8:55-9:15  Future targets for cell therapy in epithelial cancers  
Benjamin C. Creelan, Moffitt Cancer Center, Tampa, FL

9:15-9:20  Q&A

9:20-9:30  IMA203 TCR-T targeting PRAME demonstrates potent anti-tumor activity in patients with different types of metastatic solid tumors*  
Jason J. Luke, UPMC Hillman Cancer Center, Pittsburgh, PA

9:30-9:35  Q&A

Break
9:40 am-10:00 am | Level 3, Ballroom Foyer

Plenary Session 7: NK Cell Therapeutics  
Session Cochairs: Juanita S. Lopez, The Royal Marsden and Institute of Cancer Research, Sutton, England, and Jeffrey S. Miller, University of Minnesota Masonic Comprehensive Cancer Center, Minneapolis, MN

10:00-10:05  Introduction  
Juanita S. Lopez, The Royal Marsden and Institute of Cancer Research, Sutton, England

10:05-10:25  Novel NK cell engineering approaches for solid tumors  
Rizwan Romee, Dana-Farber Cancer Institute, Boston, MA

10:25-10:30  Q&A

10:30-10:50  Natural killer cells in cancer: From discovery to clinical applications  
Evren Alici, Karolinska Institutet, Huddinge, Sweden

10:50-10:55  Q&A

10:55-11:15  Targeting off-the-shelf NK cell therapy to treat cancer  
Jeffrey S. Miller, University of Minnesota Masonic Comprehensive Cancer Center, Minneapolis, MN

11:15-11:20  Q&A

11:20-11:40  Panel Discussion / Q&A

Break
11:40 am-12:00 pm | Level 3, Ballroom Foyer

Plenary Session 8: Emerging Role of Therapeutic Vaccines and mRNA in Cancer  
Session Cochairs: Karine Breckpot, Vrije University Brussels, Brussels, Belgium, and Jason J. Luke, UPMC Hillman Cancer Center, Pittsburgh, PA

12:00 pm-1:40 pm | Level 3, Ballroom AB

* - oral presentation from proffered paper
12:00-12:05  Introduction
Jason J. Luke, UPMC Hillman Cancer Center, Pittsburgh, PA

12:05-12:25  mRNA-4157 individualized neoantigen therapy: mRNA therapeutics coming of age in cancer
Robert S. Meehan, Moderna, Cambridge, MA
12:25-12:30  Q&A

12:30-12:50  Leveraging mRNA to design a next-generation cell-based therapeutic cancer vaccine
Karine Breckpot, Vrije University Brussels, Brussels, Belgium
12:50-12:55  Q&A

12:55-1:15  Personalized cancer vaccines targeting neoantigens for patients with cancer: An update on successes, challenges, and opportunities
Patrick Ott, Dana-Farber Cancer Institute, Boston, MA
1:15-1:20  Q&A
1:20-1:40  Panel Discussion / Q&A

Closing Comments and Departure
1:40 pm-1:45 pm | Level 3, Ballroom AB